TargTex

What TargTex does

TargTex S.A. is a pre-clinical stage Portuguese biopharmaceutical company founded in 2019 as a spin-off from the Instituto de Medicina Molecular João Lobo Antunes (iMM) at the University of Lisbon. The company is developing TTX101, a localized, perioperative hydrogel-based therapy that delivers an allosteric antagonist of the TRPV2 calcium channel directly into the resection cavity during glioblastoma (GBM) surgery. TTX101 is designed to release drug over several weeks — covering the treatment hiatus between surgery and standard radio/chemotherapy — to eliminate residual tumor cells and reduce recurrence. The therapeutic approach is supported by a proprietary machine-learning target-discovery platform that identified TRPV2 as an unexplored GBM target and has surfaced additional drug-target relationships across other cancer types. A dual-syringe drug-device combination delivery system has been engineered for intracranial administration, and the company is collaborating with IAG (Image Analysis Group) to incorporate AI-powered quantitative MRI (DYNAMIKA platform) for treatment-response monitoring in future clinical trials. The company has received FDA Orphan Drug Designation for TTX101 in malignant gliomas (September 2023) and is preparing for Phase 1/2a clinical trials.

TargTex is funded by approximately €2.89 million in disclosed capital — a €889,591 EU Horizon 2020 grant (2019) and a €2 million Seed Extension round in February 2022 led by Laboratórios Basi with Portugal Ventures participating — plus undisclosed EIC support in October 2025. It employs 1–10 people across offices in Torres Vedras and Lisbon, Portugal, with academic collaborations extending to University of Cambridge, ETH Zürich, and Mount Sinai Health System. The intended revenue model is out-licensing of clinical candidates to larger pharmaceutical companies after clinical milestones, with proceeds reinvested in pipeline expansion beyond GBM.

The management team comprises Dr João Seixas (CEO, co-founder; Marie Sklodowska-Curie IF, >€3M in grants, prior roles at Alfama, GSK, Galchimia, Cambridge), Dr Pedro Cal (COO; post-doc in the Bernardes group), Dr Gonçalo Bernardes (Scientific Director; Royal Society University Research Fellow, ERC grants, >€7.5M in funding, 115+ publications, Associate Professor at Cambridge), and Dr Cláudia Faria (Medical Director; neurosurgeon at Santa Maria Hospital, Head of iMM's Biobank). The company has no commercial products, no licensing transactions to date, and no disclosed revenue.

Name

TargTex

Legal name

TargTex S.A.

Website

https://targtex.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

TargTex is a pre-clinical Portuguese biopharmaceutical company developing TTX101, a perioperative hydrogel-based TRPV2 antagonist for glioblastoma, with an FDA Orphan Drug Designation and an intended out-licensing revenue model.

Ownership category

akta.pro rank

Headquarters

HQ city

Torres Vedras

HQ country

Portugal

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Licensing and Partnerships: TargTex plans to achieve licensing agreements after completing clinical milestones that demonstrate clinical value. Revenue will be generated through upfront payments, milestone payments, and royalties from licensing their clinical candidates to larger pharmaceutical companies for commercialization.
2. Pipeline Development and Reinvestment: Revenue from successful licensing agreements will be reinvested in developing backup molecules and other oncological indications beyond GBM. Strategy focuses on building sustainable pipeline across multiple cancer types.

Go-to-market motion3 records

Marketing channels5 records

Core offering

TargTex is a pre-clinical stage biopharmaceutical company developing TTX101, a hydrogel-based localized drug-device combination therapy for glioblastoma multiforme (GBM). TTX101 is an allosteric antagonist of the TRPV2 calcium channel, formulated in a biocompatible hydrogel designed for perioperative administration during brain tumor resection surgery. The company's proprietary AI platform identifies novel drug-target relationships, and the lead candidate releases its active substance over weeks to eliminate residual cancer cells during the treatment hiatus between surgery and standard-of-care radiotherapy/chemotherapy.

Product overview

TargTex is developing a portfolio of targeted oncology therapies anchored by TTX101, a first-in-class hydrogel-based localized treatment for glioblastoma multiforme (GBM). TTX101 is an allosteric antagonist of the TRPV2 calcium channel, formulated as a perioperative hydrogel for direct intracranial application during tumor resection surgery. The company's proprietary AI drug discovery platform identified this unexplored target and supports pipeline expansion. A dual-syringe drug-device combination delivery system has been developed for clinical administration of the therapeutic hydrogel. TargTex is also collaborating with IAG to apply AI-powered quantitative imaging analysis for patient response monitoring.

Differentiator

Problem solved

Functional benefit

Products and services

• TTX101 TTX101 is TargTex's lead clinical candidate, a hydrogel-based localized therapy for glioblastoma multiforme (GBM). It is an allosteric antagonist of the TRPV2 calcium channel, designed to be applied as an adjunct to surgery after tumor excision. The hydrogel releases the active substance over a period of weeks to cover the wound healing period between surgery and radiotherapy. TTX101 received FDA Orphan Drug Designation in September 2023 and is being prepared for Phase 1/2a clinical trials.

Quantifiable outcome

• Tumoral eradication demonstrated in preclinical rodent models with GBM cells injected intracranially
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• EdgeOne MedicalcoreImplementation/ SI/ Consulting Partner · 14 May 2026Strategic collaboration for independent technical and regulatory assessment of TargTex's innovative drug-device combination delivery system for brain cancers. EdgeOne Medical provides comprehensive regulatory and technical expertise to evaluate and optimize the dual-syringe hydrogel delivery platform, ensuring FDA combination product requirements alignment and accelerating clinical readiness.
• IAG (Image Analysis Group)coreTechnology or Integration · 14 February 2023TargTex partnered with IAG to apply Artificial Intelligence and quantitative imaging analysis for assessing effects of their novel clinical candidate in glioblastoma patients. IAG will utilize their DYNAMIKA AI-powered platform and multiparametric MRI imaging to identify early treatment changes, detect pseudo-progression, and develop predictive response markers. This collaboration supports precision medicine approach to monitoring patient outcomes in clinical trials.
• Instituto de Medicina Molecular (iMM)coreStrategic or Co-development PartnerTargTex originated from research at iMM (Instituto de Medicina Molecular João Lobo Antunes) at University of Lisbon. The company's basic technology was developed in Dr. Gonçalo Bernardes' research lab. Company co-founder Dr. Cláudia Faria is a researcher at iMM and iMM's Biobank provides human biospecimens for research.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Kazia Therapeutics: Kazia is developing paxalisib, a brain-penetrant PI3K inhibitor for newly diagnosed and recurrent GBM. It is a directly comparable small-molecule GBM therapeutics developer in similar clinical stage, targeting the same patient population TargTex addresses with TTX101.
• VBI Vaccines: VBI Vaccines has developed VBI-1901, a glioblastoma immunotherapy candidate evaluated in recurrent GBM. It is a directly comparable GBM-focused oncology therapeutics developer pursuing a similar patient population with a novel mechanism.
• Novocure: Novocure markets Tumor Treating Fields (TTFields) via the Optune device for newly diagnosed and recurrent GBM. It is the most direct comparable to TargTex because it pursues a localized, device-mediated therapy paradigm in the same glioblastoma indication, validating the regulatory and commercial path TargTex is targeting.
• CNS Pharmaceuticals: CNS Pharmaceuticals is developing berubicin, an anthracycline that crosses the blood-brain barrier, for recurrent GBM. It is a directly comparable GBM-focused oncology therapeutics company competing in the same indication and treatment-line as TargTex's TTX101.
• Northwest Biotherapeutics: Northwest Biotherapeutics develops DCVax-L, a personalized dendritic cell immunotherapy for newly diagnosed and recurrent GBM. It is a directly comparable GBM-focused therapeutics company pursuing a localized/standard-of-care-adjunct paradigm similar to TargTex's perioperative positioning.

Broad incumbents

• Exscientia: Exscientia is a publicly listed AI drug discovery company using machine learning to design and advance small-molecule drug candidates across multiple indications. It is comparable to TargTex as a broad AI-drug-discovery incumbent whose platform-driven model parallels TargTex's AI-identified TRPV2 program.
• Recursion Pharmaceuticals: Recursion is a leading AI-driven drug discovery company combining high-content imaging, machine learning, and wet-lab automation to identify novel targets and therapeutics. It is comparable to TargTex as a broader AI-target-identification platform operator, though operating across multiple therapeutic areas rather than focused on oncology.

Emerging players

• Black Diamond Therapeutics: Black Diamond Therapeutics is a precision oncology company developing small molecules against novel allosteric and mutant targets, including programs in CNS cancers. It is comparable to TargTex as a precision-oncology emerging player targeting hard-to-treat tumors with mechanism-driven, target-validated candidates.
• Nanobiotix: Nanobiotix develops nanoparticle-based radio-enhancer therapy (Hensify) injected intratumorally to potentiate radiotherapy in solid tumors. It is comparable to TargTex because it pursues a localized, locally-administered oncology therapy paradigm with a device-like delivery component, addressing similar tumor microenvironment challenges.
• Lantern Pharma: Lantern Pharma is an AI-driven oncology drug development company using machine learning to identify and advance oncology candidates. It is comparable to TargTex as an emerging AI-enabled precision oncology therapeutics developer with a similar small-team, platform-plus-pipeline model.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/TargTex

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TargTex